Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer
Open accessAbstract
Background: Ibrutinib is a Bruton tyrosine kinase inhibitor that is used for the treatment of lymphoid cancers, including chronic lymphocytic leukemia, Waldenström macroglobulinemia, and mantle cell lymphoma. Several case series have described opportunistic infections among ibrutinib recipients, but the full extent of these infections is unknown. We sought to determine the spectrum of serious infections associated with ibrutinib treatment. Methods: We reviewed the electronic medical records of patients with lymphoid cancer at Memorial Sloan Kettering Cancer Center who received ibrutinib during a 5-year period from 1 January 2012 to 31 December 2016. Serious infections were identified by review of the relevant microbiology, clinical laboratory, and radiology data. Risk factors for infection were determined by means of univariate and multivariate analyses. Results: We analyzed findings in 378 patients with lymphoid cancer who received ibrutinib. The most common underlying cancers were chronic lymphocytic leukemia and mantle cell lymphoma. 84% of patients received ibrutinib as monotherapy. Serious infection developed in 43 patients (11.4%), primarily during the first year of ibrutinib treatment. Invasive bacterial infections developed in 23 (53.5%) of these patients, and invasive fungal infections (IFIs) in 16 (37.2%) .The majority of patients with IFIs during ibrutinib therapy (62.5%) lacked classic clinical risk factors for fungal infection (ie, neutropenia, lymphopenia, and receipt of corticosteroids). Infection resulted in death in 6 of the 43 patients (14%). Conclusions: Patients with lymphoid cancer receiving ibrutinib treatment are at risk for serious infections, including IFIs.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Treatment of patients with lymphoproliferative malignancies with inhibitors of BTK has resulted in a surge in cases of invasive aspergillosis.
“Notably, treatment of patients with lymphoproliferative malignancies with inhibitors of BTK has resulted in a surge in cases of invasive aspergillosis (79, 264).”
From Aspergillus fumigatus and Aspergillosis in 2019 (2019) · cites this paper as [264]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917 · see citing works
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270 · see citing works
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685 · see citing works
Vetrie, D. L. P., Vořechovský, I., Sideras, P., Holland, J., Davies, A. F., Flinter, F. A., Hammarström, L. L. G., Kinnon, C., Levinsky, R. J., Bobrow, M., et al. (1993) · Nature · doi:10.1038/361226a0 · Cited by 1,460 · see citing works
Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia
Tsukada, S., Saffran, D. C., Rawlings, D. J., Parolini, O., Allen, R. C., Klisak, I. J., Sparkes, R. S., Kubagawa, H., Mohandas, T. K., Quan, S. G., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90667-f · Cited by 1,326 · see citing works
Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128 · cited 3× · see citing works
“Ibrutinib was approved by the US Food and Drug Administration for the treatment of patients with CLL, previously treated mantle cell lymphoma (MCL) or marginal zone lymphoma, WM, or refractory chronic graft-versus-host disease, and by the European Medicines Agency for the treatment of patients with CLL, WM, or previou…”
MethodIbrutinib in Previously Treated Waldenström’s Macroglobulinemia
Treon, S. P., Tripsas, C. K., Meid, K., Warren, D. L., Varma, G., Green, R., Argyropoulos, K. V., Yang, G., Cao, Y., Xu, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501548 · Cited by 939 · see citing works
Self-citationByrd, J. C., Furman, R. R., Coutre, S. E., Burger, J. A., Blum, K. A., Coleman, M., Wierda, W. G., Jones, J. A., Zhao, W., Heerema, N. A., et al. (2015) · Blood · doi:10.1182/blood-2014-10-606038 · Cited by 664 · see citing works
Colocalization of X-Linked Agammaglobulinemia and X-Linked Immunodeficiency Genes
Thomas, J. D., Sideras, P., Smith, C. I. E., Vořechovský, I., Chapman, V. M., & Paul, W. E. (1993) · Science · doi:10.1126/science.8332900 · Cited by 613 · see citing works
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy
Miklos, D. B., Cutler, C. S., Arora, M., Waller, E. K., Jagasia, M., Pusic, I., Flowers, M. E. D., Logan, A. C., Nakamura, R., Blazar, B. R., et al. (2017) · Blood · doi:10.1182/blood-2017-07-793786 · Cited by 520 · see citing works
Mohamed, A. J., Yu, L., Bäckesjö, C., Vargas, L., Faryal, R., Aints, A., Christensson, B., Berglöf, A., Vihinen, M., Nore, B. F., et al. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00741.x · Cited by 516 · see citing works
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma
Lionakis, M. S., Dunleavy, K. M., Roschewski, M. J., Widemann, B. C., Butman, J. A., Schmitz, R., Yang, Y., Cole, D. E., Melani, C. J., Higham, C. S., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.012 · Cited by 508 · see citing works
O'Brien, S. M., Furman, R. R., Coutre, S. E., Sharman, J. P., Burger, J. A., Blum, K. A., Grant, B., Richards, D., Coleman, M., Wierda, W. G., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70513-8 · Cited by 466 · see citing works
Burger, J. A., Keating, M. J., Wierda, W. G., Hartmann, E., Hoellenriegel, J., Rosin, N. Y., de Weerdt, I., Jeyakumar, G., Ferrajoli, A., Cárdenas-Turanzas, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70335-3 · Cited by 331 · see citing works
Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib
Ghez, D., Calleja, A., Protin, C. A., Baron, M., Ledoux, M., Damaj, G. L., Dupont, M., Dreyfus, B., Ferrant, E., Herbaux, C., et al. (2018) · Blood · doi:10.1182/blood-2017-11-818286 · Cited by 308 · see citing works
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma
Noy, A., de Vos, S., Thiéblemont, C., Martin, P., Flowers, C. R., Morschhauser, F., Collins, G. P., Ma, S., Coleman, M., Peles, S., et al. (2017) · Blood · doi:10.1182/blood-2016-10-747345 · Cited by 303 · see citing works
Chamilos, G., Lionakis, M. S., & Kontoyiannis, D. P. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix687 · Cited by 267 · see citing works
X-Linked Agammaglobulinemia A Clinical and Molecular Analysis
Ochs, H. D., & Smith, C. I. E. (1996) · Medicine · doi:10.1097/00005792-199611000-00001 · Cited by 266 · see citing works
Younes, A., Thiéblemont, C., Morschhauser, F., Flinn, I. W., Friedberg, J. W., Amorim, S., Hivert, B., Westin, J. R., VERMEULEN, J. T., Bandyopadhyay, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70311-0 · Cited by 254 · see citing works
Ahn, I. E., Jerussi, T., Farooqui, M. Z. H., Tian, X., Wiestner, A. U., & Gea‐Banacloche, J. (2016) · Blood · doi:10.1182/blood-2016-06-722991 · Cited by 165 · see citing works
Jongstra‐Bilen, J., Cano, A. P., Hasija, M., Xiao, H., Smith, C. I. E., & Cybulsky, M. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.288 · Cited by 132 · see citing works
Bruton’s tyrosine kinase (BTK) as a promising target in solid tumors
Molina‐Cerrillo, J., Alonso‐Gordoa, T., Gajate, P., & Grande, E. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.06.001 · Cited by 127 · see citing works
Strijbis, K., Tafesse, F., Fairn, G. D., Witte, M. D., Dougan, S. K., Watson, N., Spooner, E., Esteban, A., Vyas, V. K., Fink, G. R., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003446 · Cited by 86 · see citing works
Montagna, M. T., Giglio, O. D., Napoli, C., Lovero, G., Caggiano, G., Delia, M., Pastore, D., Santoro, N., & Specchia, G. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13010774 · Cited by 67 · see citing works
Targeting Bruton's tyrosine kinase with ibrutinib in B‐cell malignancies
Wang, Y., Zhang, L., Champlin, R., & Ml, W. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.85 · Cited by 60 · see citing works
Baron, M., Zini, J. M., Challan-Belval, T., Vignon, M., Denis, B., Alanio, A., & Malphettes, M. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1320710 · Cited by 60 · see citing works
Messina, J. A., Maziarz, E. K., Spec, A., Kontoyiannis, D. P., & Perfect, J. R. (2016) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw261 · Cited by 57 · see citing works
Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia
Arthurs, B. J., Wunderle, K., Hsu, M., & Kim, S. (2017) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2017.03.011 · Cited by 54 · see citing works
Ibrutinib for Chronic Lymphocytic Leukemia
Burger, J. A., Styles, L., & Kipps, T. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1600328 · Cited by 53 · see citing works
Disseminated Cryptococcal Disease in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib
Okamoto, K., Proia, L. A., & Demarais, P. (2016) · Case Reports in Infectious Diseases · doi:10.1155/2016/4642831 · Cited by 45 · see citing works
Current Status of Bruton’s Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies
Aw, A., & Brown, J. R. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0468-4 · Cited by 42 · see citing works
Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia
Chan, T. S. Y., Au-Yeung, R. K. H., Ho, P., Wong, S. C. Y., & Kwong, Y. (2017) · Annals of Hematology · doi:10.1007/s00277-017-2944-7 · Cited by 31 · see citing works
Ibrutinib in Chronic Lymphocytic Leukemia
Reddy, N. M., & Sethi, T. K. (2015) · International Journal of Hematologic Oncology · doi:10.2217/ijh.15.15 · Cited by 26 · see citing works
Ibrutinib‐associated Pneumocystis jirovecii pneumonia
Lee, R., Nayernama, A., Jones, S. C., Wroblewski, T., & Waldron, P. E. (2017) · American Journal of Hematology · doi:10.1002/ajh.24890 · Cited by 25 · see citing works
Visentin, A., Gurrieri, C., Imbergamo, S., Lessi, F., Maggio, S. A. D., Frezzato, F., Adami, F., Zambello, R., Piazza, F., Semenzato, G., et al. (2016) · Hematological Oncology · doi:10.1002/hon.2343 · Cited by 22 · see citing works
X-Linked Agammaglobulinemia -- GeneReviews®
Ra, P., Adam, M. P., Hh, A., Se, W., Amemiya, A., Ljh, B., Bird, T. D., Ct, F., Mefford, H. C., Rjh, S., et al. (2016) · Cited by 2 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Aspergillus fumigatus and Aspergillosis in 2019
Latgé, J.-P., & Chamilos, G. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00140-18 · Cited by 1,400 · see citing works
Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects
Estupiñan, H. Y., Berglöf, A., Zain, R., & Smith, C. I. E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.630942 · Cited by 272 · see citing works
Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
Davis, J. S., Ferreira, D., Paige, E. K., Gedye, C. A., & Boyle, M. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00035-19 · Cited by 188 · see citing works
(ECIL), O. B. O. T. E. C. O. I. I. L., Maschmeyer, G., Greef, J. D., Mellinghoff, S. C., Nosari, A., Thiébaut, A., Bergeron, A., Franquet, T., Blijlevens, N. M. A., & Maertens, J. A. (2019) · Leukemia · doi:10.1038/s41375-019-0388-x · Cited by 184 · see citing works
Managing toxicities of Bruton tyrosine kinase inhibitors
Lipsky, A. H., & Lamanna, N. (2020) · Hematology · doi:10.1182/hematology.2020000118 · Cited by 171 · see citing works
Mucormycosis of the Central Nervous System
Chikley, A., Ben‐Ami, R., & Kontoyiannis, D. P. (2019) · Journal of Fungi · doi:10.3390/jof5030059 · Cited by 143 · see citing works
Dreger, P., Ghia, P., Schetelig, J., van Gelder, M., Kimby, E. K., Michallet, M., Moreno, C., Robak, T., Stilgenbauer, S., & Montserrat, E. (2018) · Blood · doi:10.1182/blood-2018-01-826008 · Cited by 104 · see citing works
A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia
Chen, L. S., Bose, P., Cruz, N. D., Jiang, Y., Wu, Q., Thompson, P. A., Feng, S., Kroll, M. H., Qiao, W., Huang, X., et al. (2018) · Blood · doi:10.1182/blood-2018-06-860593 · Cited by 102 · see citing works
Rendeiro, A. F., Krausgruber, T., Fortelny, N., Zhao, F., Penz, T., Farlik, M., Schuster, L. C., Nemc, A., Tasnády, S., Réti, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14081-6 · Cited by 96 · see citing works
Morjaria, S. M., Frame, J., Franco-Garcia, A., Geyer, A. I., Kamboj, M., & Babady, N. E. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy1072 · Cited by 92 · see citing works
Teh, B. W., Yeoh, D. K., Haeusler, G. M., Yannakou, C. K., Fleming, S. A., Lindsay, J., & Slavin, M. A. (2021) · Internal Medicine Journal · doi:10.1111/imj.15588 · Cited by 89 · see citing works
The Pathogenesis and Diagnosis of Pneumocystis jiroveci Pneumonia
Apostolopoulou, A., & Fishman, J. A. (2022) · Journal of Fungi · doi:10.3390/jof8111167 · Cited by 89 · see citing works
Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies
Rogers, K. A., Mousa, L., Zhao, Q., Bhat, S. A., Byrd, J. C., Boghdadly, Z. E., Guerrero, T., Levine, L. B., Lucas, F. M., Shindiapina, P., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0481-1 · Cited by 88 · see citing works
Thibaud, S., Tremblay, D. A., Bhalla, S., Zimmerman, B. S., Sigel, K. M., & Gabrilove, J. L. (2020) · British Journal of Haematology · doi:10.1111/bjh.16863 · Cited by 84 · see citing works
Ruchlemer, R., Ben‐Ami, R., Bar‐Meir, M., Brown, J. R., Malphettes, M., Mous, R., Tonino, S. H., Soussain, C., Barzic, N., Messina, J. A., et al. (2019) · Mycoses · doi:10.1111/myc.13001 · Cited by 82 · see citing works
BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects
Palma, M., Mulder, T. A., & Österborg, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.686768 · Cited by 81 · see citing works
Nucci, M., & Anaissie, E. J. (2023) · Clinical Microbiology Reviews · doi:10.1128/cmr.00159-22 · Cited by 79 · see citing works
Mauro, F. R., Giannarelli, D., Galluzzo, C. M., Vitale, C., Visentin, A., Riemma, C., Rosati, S., Porrazzo, M., Pepe, S., Coscia, M., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0884-z · Cited by 78 · see citing works
Invasive Pulmonary Aspergillosis
Ledoux, M., & Herbrecht, R. (2023) · Journal of Fungi · doi:10.3390/jof9020131 · Cited by 76 · see citing works
Liévin, R., Blasi, R. D., Morin, F., Galli, E., Allain, V., de Jorna, R., Vercellino, L., Parquet, N., Mebarki, M., Larghero, J., et al. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01526-0 · Cited by 73 · see citing works
Mucosal IgA Prevents Commensal Candida albicans Dysbiosis in the Oral Cavity
Millet, N., Solis, N. V., & Swidergall, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.555363 · Cited by 68 · see citing works
Robak, T., Witkowska, M., & Smolewski, P. (2022) · Cancers · doi:10.3390/cancers14030771 · Cited by 68 · see citing works
Invasive pulmonary aspergillosis in critically ill patients with hematological malignancies
Pardo, E., Lemiale, V., Mokart, D., Stoclin, A., Moreau, A., Kerhuel, L., Calvet, L., Valade, S., JONG, A. D., Darmon, M., et al. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05789-6 · Cited by 67 · see citing works
Second cancer incidence in CLL patients receiving BTK inhibitors
Bond, D. A., Huang, Y., Fisher, J. L., Ruppert, A. S., Owen, D. H., Bertino, E. M., Rogers, K. A., Bhat, S. A., Grever, M. R., Jaglowski, S. M., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0987-6 · Cited by 64 · see citing works
Menacing Mold: Recent Advances in Aspergillus Pathogenesis and Host Defense
Tischler, B. Y., & Hohl, T. M. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.03.027 · Cited by 55 · see citing works
Self-citationMorrissey, C. O., Kim, H. Y., Duong, T.-M. N., Moran, E., Alastruey‐Izquierdo, A., Denning, D. W., Perfect, J. R., Nucci, M., Chakrabarti, A., Rickerts, V., et al. (2024) · Medical Mycology · doi:10.1093/mmy/myad129 · Cited by 55 · see citing works
Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia
Banerjee, P., Zhang, R., Ivan, C., Galletti, G., Clise-Dwyer, K., Barbaglio, F., Scarfò, L., Aracil, M., Klein, C., Wierda, W. G., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0152 · Cited by 54 · see citing works
Shariati, A., Moradabadi, A., Chegini, Z., Khoshbayan, A., & Didehdar, M. (2020) · Infection and Drug Resistance · doi:10.2147/idr.s254478 · Cited by 55 · see citing works
Liposomal amphotericin B—the present
Maertens, J. A., Pagano, L., Azoulay, É., & Warris, A. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac352 · Cited by 53 · see citing works
Why are so many cases of invasive aspergillosis missed?
Danion, F., Rouzaud, C., Dureault, A., Poirée, S., Bougnoux, M., Alanio, A., Lanternier, F., & Lortholary, O. (2018) · Medical Mycology · doi:10.1093/mmy/myy081 · Cited by 52 · see citing works
Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies
Little, J. S., Weiss, Z., & Hammond, S. P. (2021) · Journal of Fungi · doi:10.3390/jof7121058 · Cited by 53 · see citing works
Bergamasco, M. D., Pereira, C. A. P., Arrais‐Rodrigues, C., Ferreira, D. B., Baiocchi, O. C. G., Kerbauy, F. R., Nucci, M., & Colombo, A. L. (2021) · Journal of Fungi · doi:10.3390/jof7080588 · Cited by 50 · see citing works
Fiorcari, S., Maffei, R., Vallerini, D., Scarfò, L., Barozzi, P., Maccaferri, M., Potenza, L., Ghia, P., Luppi, M., & Marasca, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02158 · Cited by 51 · see citing works
Risk of infection associated with targeted therapies for solid organ and hematological malignancies
Ruíz-Camps, I. (2021) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936121989548 · Cited by 48 · see citing works
Vaccination of the Stem Cell Transplant Recipient and the Hematologic Malignancy Patient
Kamboj, M., & Shah, M. K. (2019) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2019.02.007 · Cited by 48 · see citing works
Fungal Infections with Ibrutinib and Other Small-Molecule Kinase Inhibitors
Zarakas, M. A., Desai, J. V., Chamilos, G., & Lionakis, M. S. (2019) · Current Fungal Infection Reports · doi:10.1007/s12281-019-00343-9 · Cited by 47 · see citing works
Terpos, E., Gavriatopoulou, M., Fotiou, D., Giatra, C., Asimakopoulos, I., Dimou, M., Sklirou, A. D., Ntanasis‐Stathopoulos, I., Darmani, I., Briasoulis, Α., et al. (2021) · Cancers · doi:10.3390/cancers13174480 · Cited by 46 · see citing works
Ryan, C. E., Cheng, M. P., Issa, N. C., Brown, J. R., & Davids, M. S. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001678 · Cited by 46 · see citing works
Miesel, L., Cushion, M. T., Ashbaugh, A., Lopez, S. R., & Ong, V. S. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01992-20 · Cited by 47 · see citing works
Langerbeins, P., & Eichhorst, B. F. (2021) · Acta Haematologica · doi:10.1159/000514071 · Cited by 44 · see citing works
Targeting ITK signaling for T cell-mediated diseases
Weeks, S., Harris, R., & Karimi, M. A. (2021) · iScience · doi:10.1016/j.isci.2021.102842 · Cited by 43 · see citing works
Harnessing the Potential of Multiomics Studies for Precision Medicine in Infectious Disease
Ward, R., Aghaeepour, N., Bhattacharyya, R. P., Clish, C. B., Gaudilliere, B. L., Hacohen, N., Mansour, M. K., Mudd, P. A., Pasupneti, S., Presti, R. M., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab483 · Cited by 45 · see citing works
Tapaninen, T., Olkkola, A. M., Tornio, A., Neuvonen, M., Elonen, E., Neuvonen, P. J., Niemi, M., & Backman, J. T. (2019) · Clinical and Translational Science · doi:10.1111/cts.12716 · Cited by 44 · see citing works
Gavriatopoulou, M., Terpos, E., Ntanasis‐Stathopoulos, I., Briasoulis, Α., Gumeni, S., Malandrakis, P., Fotiou, D., Migkou, M., Theodorakakou, F., Eleutherakis‐Papaiakovou, E., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005444 · Cited by 42 · see citing works
Huang, S., Wu, A. Y.-J., Lee, S. S., Huang, Y., Lee, C.-Y., Yang, T.-L., Wang, H.-W., Chen, H.-J., Chen, Y. C., Ho, T., et al. (2022) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2022.12.004 · Cited by 44 · see citing works
Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections
Maffei, R., Maccaferri, M., Arletti, L., Fiorcari, S., Benatti, S., Potenza, L., Luppi, M., & Marasca, R. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100635 · Cited by 41 · see citing works
The CoV-2 outbreak: how hematologists could help to fight Covid-19
Galimberti, S., Baldini, C., Baratè, C., Ricci, F., Balducci, S., Grassi, S., Ferro, F., Buda, G., Benedetti, E., Fazzi, R., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104866 · Cited by 41 · see citing works
Inhibiting Bruton’s Tyrosine Kinase in CLL and Other B-Cell Malignancies
Lucas, F. M., & Woyach, J. A. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00635-7 · Cited by 40 · see citing works
Aspergillosis: Emerging risk groups in critically ill patients
Kluge, S., Strauß, R., Kochanek, M., Weigand, M. A., Rohde, H., & Lahmer, T. (2021) · Medical Mycology · doi:10.1093/mmy/myab064 · Cited by 39 · see citing works
BTK drives neutrophil activation for sterilizing antifungal immunity
Desai, J. V., Zarakas, M. A., Wishart, A. L., Roschewski, M. J., Aufiero, M. A., Donkó, Á., Wigerblad, G., Shlezinger, N., Plate, M., James, M. R., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci176142 · Cited by 39 · see citing works
Self-citationInfectious disease considerations in immunocompromised patients
McGrath, B. A., Broadhurst, M., & Roman, C. (2020) · JAAPA · doi:10.1097/01.jaa.0000694948.01963.f4 · Cited by 36 · see citing works
Ahmed, K. R., Rahman, M. M., Islam, M. N., Fahim, M. M. H., Rahman, M. A., & Kim, B. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116497 · Cited by 34 · see citing works
Ball, S., Das, A., Vutthikraivit, W., Edwards, P. J., Hardwicke, F. L., Short, N. J., Borthakur, G. M., & Maiti, A. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.10.004 · Cited by 31 · see citing works
Frei, M., Aitken, S. L., Jain, N., Thompson, P. A., Wierda, W. G., Kontoyiannis, D. P., & DiPippo, A. J. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1775215 · Cited by 31 · see citing works
Fungal Infections Associated With the Use of Novel Immunotherapeutic Agents
Bernardes, M., & Hohl, T. M. (2020) · Current Clinical Microbiology Reports · doi:10.1007/s40588-020-00154-4 · Cited by 31 · see citing works
Self-citationChu, S., McCormick, T. S., Lazarus, H. M., Leal, L. O., & Ghannoum, M. A. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108731 · Cited by 30 · see citing works
Tavakoli, G. M., Yazdanpanah, N., & Rezaei, N. (2024) · Revista Brasileira de Reumatologia · doi:10.1186/s42358-024-00401-y · Cited by 32 · see citing works
Mauro, F. R., Giannarelli, D., Visentin, A., Reda, G., Sportoletti, P., Frustaci, A. M., Chiarenza, A., Ciolli, S., Vitale, C., Laurenti, L., et al. (2021) · Cancers · doi:10.3390/cancers13133240 · Cited by 27 · see citing works
Gold, J. A. W., Tolu, S. S., Chiller, T. M., Benedict, K., & Jackson, B. R. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1026 · Cited by 25 · see citing works
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia
Tettamanti, S., Rotiroti, M. C., Attianese, G. M. P. G., Arcangeli, S., Zhang, R., Banerjee, P., Galletti, G., McManus, S. D., Mazza, M., Nicolini, F., et al. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2043299 · Cited by 25 · see citing works
Mancuso, S., Mattana, M., Carlisi, M., Santoro, M., & Siragusa, S. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063368 · Cited by 27 · see citing works
Pagano, L., & Facchinelli, D. (2018) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2018.063 · Cited by 23 · see citing works
Teh, B. W., Chui, W. C. M., Handunnetti, S. M., Tam, C. S. L., Worth, L. J., Thursky, K., & Slavin, M. A. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1543884 · Cited by 23 · see citing works
Invasive Aspergillosis in Patients Treated With Ibrutinib
Fürstenau, M., Simon, F., Cornely, O. A., Hicketier, T., Eichhorst, B. F., Hallek, M. J., & Mellinghoff, S. C. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000309 · Cited by 23 · see citing works
Pouvaret, A., Guéry, R., Montillet, M., Molina, T. J., Dureault, A., Bougnoux, M., Galliot, R., Lanternier, F., Delarue, R., & Lortholary, O. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.01.016 · Cited by 23 · see citing works
How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS‐CoV‐2 Pandemic
Rossi, D., Shadman, M. S., Condoluci, A., Brown, J. R., Byrd, J. C., Gaïdano, G., Hallek, M. J., Hillmen, P., Mato, A. R., Montserrat, E., et al. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000432 · Cited by 22 · see citing works
Alkharabsheh, O. A., Alsayed, A., Morlote, D. M., & Mehta, A. (2021) · Current Oncology · doi:10.3390/curroncol28010081 · Cited by 22 · see citing works
Small-Molecule Protein Kinases Inhibitors and the Risk of Fungal Infections
Bechman, K., Galloway, J. B., & Winthrop, K. L. (2019) · Current Fungal Infection Reports · doi:10.1007/s12281-019-00350-w · Cited by 22 · see citing works
Cryptococcosis Associated With Biologic Therapy: A Narrative Review
Li, X., Paccoud, O., Chan, K. H., Yuen, K., Manchon, R., Lanternier, F., Slavin, M. A., van de Veerdonk, F. L., Bicanic, T. A., & Lortholary, O. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae316 · Cited by 21 · see citing works
Pidala, J. A., Kim, J., Kalos, D., Cutler, C. S., DeFilipp, Z. M., Flowers, M. E. D., Hamilton, B. K., Chin, K., Rotta, M., Jurdi, N. E., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014374 · Cited by 21 · see citing works
Dalal, N., Dores, G. M., Curtis, R. E., Linet, M. S., & Morton, L. M. (2020) · British Journal of Haematology · doi:10.1111/bjh.16492 · Cited by 21 · see citing works
Safety Profile of Ibrutinib: An Analysis of the WHO Pharmacovigilance Database
Allouchery, M., Tomowiak, C., Lombard, T., Pérault‐Pochat, M., & Salvo, F. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.769315 · Cited by 21 · see citing works
Infections in patients with chronic lymphocytic leukemia
Guaraná, M., & Nucci, M. (2023) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2023.05.006 · Cited by 21 · see citing works
Ibrutinib in CLL/SLL: From bench to bedside (Review)
Zi, F., Li, Y., Shi, Q., Tang, A., & Cheng, J. (2019) · Oncology Reports · doi:10.3892/or.2019.7364 · Cited by 21 · see citing works
Infante, M. S., Fernández‐Cruz, A., Núñez, L., Carpio, C. D. C., Ubieto, A. J., López‐Jiménez, J., Vásquez, L., Campo, R. D., Romero, S., Alonso, C., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.4293 · Cited by 20 · see citing works
Avalon, J. C., Fuqua, J. L., Miller, T. C., Deskins, S. J., Wakefield, C., King, A., Inderbitzin-Brooks, S., Bianco, C. M., Veltri, L. W., Fang, W., et al. (2021) · Cardio-Oncology · doi:10.1186/s40959-021-00125-8 · Cited by 19 · see citing works
Mikulska, M., Oltolini, C., Zappulo, E., Bartoletti, M., Frustaci, A. M., Visentin, A., Vitale, C., & Mauro, F. R. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101180 · Cited by 20 · see citing works
Non‐Aspergillus invasive mould infections in patients treated with ibrutinib
Anastasopoulou, A. N., DiPippo, A. J., & Kontoyiannis, D. P. (2020) · Mycoses · doi:10.1111/myc.13120 · Cited by 20 · see citing works
Prezzo, A., Cavaliere, F. M., Bilotta, C., Pentimalli, T. M., Iacobini, M., Cesini, L., Foà, R., Mauro, F. R., & Quinti, I. (2019) · Leukemia Research · doi:10.1016/j.leukres.2019.106233 · Cited by 19 · see citing works
Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis
Nocco, S. E., Andriano, T. M., Bose, A., Chilov, M., Godwin, K., Dranitsaris, G., Wu, S., Lacouture, M. E., Roeker, L. E., Mato, A. R., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103696 · Cited by 20 · see citing works
Isavuconazole for the treatment of invasive fungal disease in patients receiving ibrutinib
Cummins, K. C., Cheng, M. P., Kubiak, D. W., Davids, M. S., Marty, F. M., & Issa, N. C. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1485913 · Cited by 19 · see citing works
Song, X., Rao, H., Guo, C., Yang, B., Ren, Y., Wang, M., Li, Y., Cao, Z., & Pei, J. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153802 · Cited by 19 · see citing works
Odeny, T., Fink, V. I., Muchengeti, M. M., & Gopal, S. (2024) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2024.06.007 · Cited by 18 · see citing works
Majumdar, A., Shah, M. R., Park, J. J., Narayanan, N., Kaye, K. S., & Bhatt, P. J. (2023) · Antibiotics · doi:10.3390/antibiotics12030592 · Cited by 18 · see citing works
Ibrutinib Therapy and Mycobacterium chelonae Skin and Soft Tissue Infection
Dousa, K. M., Babiker, A., Aartsen, D. V., Shah, N. B., Bonomo, R. A., Johnson, J. L., & Skalweit, M. J. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy168 · Cited by 18 · see citing works
Ohmoto, A., & Fuji, S. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100738 · Cited by 18 · see citing works
Infections associated with the new ‘nibs and mabs’ and cellular therapies
Maus, M. V., & Lionakis, M. S. (2020) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000656 · Cited by 18 · see citing works
The Right Dose: From Phase I to Clinical Practice
Groenland, S. L., Ratain, M. J., Chen, L. S., & Gandhi, V. V. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_319567 · Cited by 17 · see citing works
Marchesini, G., Nadali, G., Facchinelli, D., Candoni, A., Cattaneo, C. M., Laurenti, L., Fanci, R., Farina, F., Lessi, F., Visentin, A., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.17145 · Cited by 17 · see citing works
Chilson, E. L., Scott, D. A., Schmöele-Thoma, B., Watson, W. K., Moran, M. M., & Istúriz, R. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1735224 · Cited by 16 · see citing works
Zinzani, P. L., Rambaldi, A., Gaïdano, G., Girmenia, C., Marchetti, M., Pane, F., Tura, S., & Barosi, G. (2019) · Leukemia Research · doi:10.1016/j.leukres.2019.04.016 · Cited by 16 · see citing works
Fehr, M., Cathomas, G., Graber, A., Makert, E., Gaus, E., & Boggian, K. (2019) · Medical Mycology Case Reports · doi:10.1016/j.mmcr.2019.12.005 · Cited by 16 · see citing works
Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma
Makita, S., Hosoba, R., & Tobinai, K. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1802424 · Cited by 17 · see citing works
Liposomal amphotericin B—the future
Hoenigl, M., Lewis, R. E., van de Veerdonk, F. L., Verweij, P. E., & Cornely, O. A. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac353 · Cited by 17 · see citing works
Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis
Brochard, J., Morio, F., Mahé, J., Pape, P. L., Guimard, T., Mahé, B., Leterrier, M., Morrier, M., Raffi, F., & Boutoille, D. (2020) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2020.07.005 · Cited by 16 · see citing works
Lymphocyte migration and retention properties affected by ibrutinib in chronic lymphocytic leukemia
Rey-Barroso, J., Munaretto, A., Rouquié, N., Mougel, A., Chassan, M., Gadat, S., Dewingle, O., Poincloux, R., Cadot, S., Ysebaert, L., et al. (2023) · Haematologica · doi:10.3324/haematol.2022.282466 · Cited by 16 · see citing works
Higuita, N. I. A., Chastain, D. B., Scott, B., Sahra, S., Barahona, L. V., Henao-Cordero, J., Lee, A. L.-H., Tuells, J., & Henao‐Martínez, A. F. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae115 · Cited by 15 · see citing works
Vargas-Blanco, D. A., Hepworth, O. W., Basham, K. J., Simaku, P., Crossen, A. J., Timmer, K. D., Hopke, A. R., Brown, H. E., Vandal, S. R., Jensen, K. N., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.176162 · Cited by 16 · see citing works
Eichenberger, E. M., Saullo, J. L., Brander, D. M., Wang, S. J., Perfect, J. R., & Messina, J. A. (2019) · Medical Mycology Case Reports · doi:10.1016/j.mmcr.2019.12.007 · Cited by 15 · see citing works
Cutaneous mucormycosis in a chronic lymphocytic leukemia patient on ibrutinib
Sittig, K. R., Laageide, L. G., Akhtar, Z., Wall, G. C., & Kumar, S. C. (2021) · IDCases · doi:10.1016/j.idcr.2021.e01120 · Cited by 15 · see citing works
- Authors
- Varughese, T., Taur, Y., Cohen, N., Palomba, M. L., Seo, S. K., Hohl, T. M., & Redelman-Sidi, G.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Infectious Diseases Service, Memorial Sloan Kettering Cancer Center
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-04-27
- Volume
- 67
- Issue
- 5
- Pages
- 687-692
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC6093991
- OpenAlex
- W2789508123
- Cited by
- 271
- References
- 36
- Citations by year
- 2026: 14 · 2025: 23 · 2024: 25 · 2023: 25 · 2022: 26 · 2021: 50 · 2020: 56 · 2019: 36 · 2018: 15
- FWCI
- 14.75
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Clinical Infectious Diseases (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (P30 CA008748)
- National Institutes of Health (K08 CA184038)
- Topics
- Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
- Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Keywords
- ibrutinib, serious infections, lymphoid malignancies, chronic lymphocytic leukemia, mantle cell lymphoma, Waldenström macroglobulinemia, BTK inhibitors, invasive fungal infections, invasive bacterial infection, infection risk factors, opportunistic infections
- MeSH terms
- Invasive Fungal Infections, Adenine, Adult, Aged, Aged, 80 and over, Bacterial Infections, Female, Humans, Lymphopenia, Male, Middle Aged, New York, Opportunistic Infections, Piperidines, Pyrazoles, Pyrimidines, Risk Factors, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell, Young Adult, Electronic Health Records
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
